Innovative Blood Clotting Technology Granted Patent in US

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Today Q-Sera Pty Ltd announced that it has received a Notice of Allowance from the United States Patent & Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes.

Q-Sera’s technology now has patent protection for use in blood collection tubes in the United States, Europe, Japan, China, Mexico, Russia, Canada, South Africa and Australia. Q-Sera is progressing additional patents to cover novel formulations and expanded uses for its unique actives, extending the commercial opportunities.

Q-Sera has harnessed prothrombin activators found in the venom of some of the world’s deadliest snakes, particularly the Australian Coastal Taipan, to clot blood samples producing serum for analysis. However, Q-Sera is now able to produce the cost-effective RAPClotTM protein from modified cell lines using standard pharmaceutical manufacturing processes.

Serum is the gold standard for biochemical analysis of blood samples however current technologies are unable to routinely produce high-quality serum for biochemical analysis from all samples. Q-Sera’s technology seeks to improve laboratory efficiencies by reducing time for sample analysis (turn-around time) with consistently high-quality serum. Standard serum tubes which are based on silica require up to 30 minutes to clot blood, can clot poorly leading to laboratory issues and are unable to clot anticoagulated blood from patients treated with blood thinners such as warfarin, heparin or the newer oral anticoagulants.

Q-Sera notes they aim to provide a ‘universal’ serum tube with these advantages which is cost-effective. Thrombin-based serum tubes are faster than a standard serum tube, however can cost up to five times more, and are still unable to clot anticoagulated blood at high levels.

Q-Sera’s technology has recently been published in a peer-reviewed study “Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high-quality serum from normal samples”, (Clinical Chemical Laboratory Medicine Volume 57, Issue 4). The study finds that Q-Sera’s technology demonstrates rapid generation of high-quality serum from normal samples, potentially contributing to faster turn-around times.

The Q-Sera technology is based on the research of a team of scientists from The University of Queensland, Australia (UQ). It was licensed to Q-Sera by UniQuest, UQ’s commercialisation company and has received investment from two of Australia’s premier innovation sector investors, the Medical Research Commercialisation Fund (MRCF), managed by Australia’s largest venture capital firm Brandon Capital Partners, and Uniseed who along with other institutional investors have funded Q-Sera’s activities.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles